News Astellas suffers pancreatic cancer failure with Vyloy Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.
News Poll paints picture of menopause discrimination at work A survey of women across six countries has found more than a third have experienced some kind of negative impact in the workplace due to menopause.
News NICE backs bladder cancer duo that can double survival A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green light for NHS use.
News Padcev/Keytruda extends survival in early bladder cancer Astellas and Pfizer plan to file Padcev for earlier-stage bladder cancer after showing a survival benefit in a combination regimen with Keytruda.
Oncology On the forefront of healthcare change, turning innovative sc... Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.
News Astellas adds to claudin clout with $1.3bn+ Evopoint deal Astellas was the first company to bring a drug against the claudin target CLDN18.2 to market, and has now added another to its cancer pipeline.
News Free Wegovy trialled in deprived areas of Scotland Thousands of people from Scotland's most deprived areas will get free weight-loss jabs in a real-world study to gauge if they can save the NHS money.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
